Spots Global Cancer Trial Database for Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Official Title: Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study ID: NCT05318391

Conditions

Lymphoma, Large B-Cell, Diffuse

Gene Expression Profiling

Interventions

Gene expression profile

Study Description

Brief Summary: The purpose of the study is to investigate the proportion of the cell-of-origin (COO) subtypes in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with BTK inhibitor or lenalidomide and its biosimilars.

Detailed Description: This is a multi-center, observational, retrospective study that examines approximately 200 R/R DLBCL patients treated with BTK inhibitors or lenalidomide and its biosimilars. For patients meet the inclusion criteria, gene expression analysis is performed on formalin fixed paraffin-embedded tissue by using Canhelp-COO Assay, and determine the COO subtype for each specimen. The proportion of COO subtypes in R/R DLBCL and the correlation between COO subtypes and clinicopathological information are further analyzed.